COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Por:
Lee MH, Li HJ, Wasuwanich P, Kim SE, Kim JY, Jeong GH, Park S, Yang JW, Kim MS, Yon DK, Lee SW, Koyanagi A, Jacob L., Kim EY, Cheon JH, Shin JI and Smith L
Publicada:
1 mar 2023
Ahead of Print:
11 dic 2022
Resumen:
The susceptibility, risk factors, and prognosis of COVID-19 in patients with inflammatory bowel disease (IBD) remain unknown. Thus, our study aims to assess the prevalence and clinical outcomes of COVID-19 in IBD. We searched PubMed, EMBASE, and medRxiv from 2019 to 1 June 2022 for cohort and case-control studies comparing the prevalence and clinical outcomes of COVID-19 in patients with IBD and in the general population. We also compared the outcomes of patients receiving and not receiving 5-aminosalicylates (ASA), tumour necrosis factor antagonists, biologics, systemic corticosteroids, or immunomodulators for IBD. Thirty five studies were eligible for our analysis. Pooled odds ratio of COVID-19-related hospitalisation, intensive care unit (ICU) admission, or death in IBD compared to in non-IBD were 0.58 (95% confidence interval (CI) = 0.28-1.18), 1.09 (95% CI = 0.27-4.47), and 0.67 (95% CI = 0.32-1.42), respectively. Inflammatory bowel disease was not associated with increased hospitalisation, ICU admission, or death. Susceptibility to COVID-19 did not increase with any drugs for IBD. Hospitalisation, ICU admission, and death were more likely with 5-ASA and corticosteroid use. COVID-19-related hospitalisation (Odds Ratio (OR): 0.53; 95% CI = 0.38-0.74) and death (OR: 0.13; 95% CI = 0.13-0.70) were less likely with Crohn's disease than ulcerative colitis (UC). In conclusion, IBD does not increase the mortality and morbidity of COVID-19. However, physicians should be aware that additional monitoring is needed in UC patients or in patients taking 5-ASA or systemic corticosteroids.
Filiaciones:
Lee MH:
Yonsei University College of Medicine, Seoul, Republic of Korea
Li HJ:
University of Florida College of Medicine, University of Florida, Gainesville, Florida, USA
Wasuwanich P:
University of Florida College of Medicine, University of Florida, Gainesville, Florida, USA
Kim SE:
Yonsei University College of Medicine, Seoul, Republic of Korea
Kim JY:
Yonsei University College of Medicine, Seoul, Republic of Korea
Jeong GH:
Gyeongsang National University College of Medicine, Jinju, Republic of Korea
Park S:
Yonsei University College of Medicine, Seoul, Republic of Korea
Yang JW:
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Kim MS:
Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
Yon DK:
Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, Korea
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea
Lee SW:
Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
Koyanagi A:
Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, ISCIII, Barcelona, Spain
ICREA, Barcelona, Spain
Jacob L.:
Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, ISCIII, Barcelona, Spain
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
Kim EY:
Department of Health, Social and Clinical Pharmacy, Evidence-Based and Clinical Research Laboratory, College of Pharmacy, Chung-Ang University, Seoul, Korea
Cheon JH:
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Shin JI:
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
Smith L:
The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
Green Published
|